SuperworthEvolent Health EVH
- Market cap
- $542.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.1B
- −5% on a year ago
- Net margin
- −24.1%
- Free cash flow yield
- n/m
- not a meaningful number
Evolent Health trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.1B over the last twelve months, down 5% on a year earlier with a −24% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $511M+45% | $556.1M+45% | $639.7M+50% | $647.1M+38% | $621.4M+22% | $646.5M+16% | $483.6M−24% | $444.3M−31% | $479.5M−23% | $468.7M−28% | $496.2M+3% | $652.5M+47% | |
| Cost of revenue | $386.6M+45% | $454.4M+52% | $535.5M+73% | $540.3M+54% | $540.7M+40% | $570.8M+26% | $381.2M−29% | $343.9M−36% | $379.8M−30% | $371.5M−35% | $412.5M+8% | $571.7M+66% |
| Gross profit | $124.4M+45% | $101.6M+22% | $104.1M−11% | $106.8M−9% | $80.7M−35% | $75.7M−26% | $102.5M−2% | $100.4M−6% | $99.8M+24% | $97.3M+29% | $83.8M−18% | $80.8M−20% |
| SG&A | $96.6M+41% | $81.4M−2% | $79.1M−12% | $69.2M−24% | $67.1M−31% | $47.7M−41% | $78.4M−1% | $75.2M+9% | $77.6M+16% | $72.7M+52% | $72.8M−7% | $68.8M−9% |
| −$17.9M | −$21.4M+1037% | −$13.4M+30% | $7.8M | −$16.3M−9% | −$18.6M−13% | −$1.6M−88% | −$1.2M | $886K | −$408.2M+2095% | −$10.6M+554% | −$9.6M+717% | |
| Interest expense | $14.6M+207% | $12.2M+90% | $6M−54% | $6M−59% | $6M−59% | $6.7M−45% | $10.4M+73% | $11.6M+94% | $16.5M+174% | $19M+183% | $16.9M+62% | $16.9M+45% |
| Pre-tax income | −$30.9M−29% | −$48.1M+370% | −$16.7M−81% | $1.4M | −$23.8M−23% | −$23.9M−50% | −$63.1M+278% | −$20.7M | −$20M−16% | −$430.8M+1701% | −$25.7M−59% | −$25.6M+24% |
| −$5.5M−88% | −$14.7M | $565K | −$238K−76% | −$619K−89% | −$1.1M−92% | $1.5M+160% | −$825K+247% | $906K | −$1.7M+50% | $910K−38% | $2.7M | |
| Net income | −$25.3M | −$33.4M+194% | −$17.3M−14% | $1.6M | −$23.1M−9% | −$22.8M−32% | −$64.6M+274% | −$19.9M | −$20.9M−10% | −$429.1M+1782% | −$26.6M−59% | −$28.4M+43% |
| −$0.30 | −$0.36+227% | −$0.22−8% | −$0.06−84% | −$0.27−10% | −$0.27−25% | −$0.63+186% | −$0.44+633% | −$0.24−11% | −$3.84+1322% | −$0.24−62% | −$0.25−43% | |
| 112.3M+13% | 113.6M+14% | 114.1M+6% | 114.7M+3% | 114.9M+2% | 115M+1% | 115.3M+1% | 115.9M+1% | 114.1M−1% | 111.6M−3% | 111.9M−3% | 112.5M−3% |
Revenue: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Gross profit: 21 periods, Q2 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
SG&A: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Operating income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Income tax: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
Net income: Q1 FY14 and Q1 FY15: 6 months less the 3 months printed beside them.
EPS, diluted: 4 periods, Q1 FY14 to Q4 FY22: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY14: share-days: the 6-month average less the second quarter's. 12 periods, Q4 FY14 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Specialty Business Services nearest Evolent Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EVHEvolent Health | $542.7M | n/m | n/a | 0.3× | −5% | −24.1% | |
| CRAICRA International | $1.3B | 26.6× | 21.9× | 1.6× | +11% | 6.2% | |
| DFINDonnelley Financial Solutions | $1.4B | 38.3× | 18.8× | 1.8× | +3% | 4.5% | |
| FCFranklin Covey | $211M | 110× | 34.8× | 0.8× | −6% | 0.8% | |
| VVXV2X | $2.3B | 25.5× | 14.9× | 0.5× | +13% | 1.9% | |
| MHMcGraw Hill | $2.8B | 29.2× | 28.6× | 1.3× | +0% | 4.4% | |
| Peer median | $1.4B | 29.2× | 21.9× | 1.3× | +3% | 4.4% |
More on Evolent Health
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Specialty Business Services
- Sector
- Industrials
Valuation data, not investment advice. Prices as of .